Edwards Lifesciences vs Stryker: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Edwards Lifesciences Corp (EW)

Q3 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

August 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Latest30 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Stryker Corporation (SYK)

Q3 202618 Jul – 8 Sep 2026

▲3▼1

Stryker's strong Q2 beat offset by supply snag and joint replacement weakness

Q2 beat and raised guidance Stryker's Q2 sales rose 9.4% to $6.6B and adjusted EPS hit $3.69, beating expectations, prompting management to raise full-year guidance. This shows the core business is healthy and growing faster than expected.
This is the main positive fundamental driver for the period, showing strong financial performance.
Mako robotics milestone and new product launch Mako robotics surpassed 2.5 million procedures, and Stryker launched the Mako RPS handheld knee system. These innovations strengthen Stryker's position in the growing healthcare robotics market and support future demand.
Highlights technological leadership and new product momentum, key for long-term growth.
$100M defense contract and tech partnerships Stryker won a $100M defense contract and advanced acquisitions and Apple Vision Pro technology. This government validation and tech integration open new revenue streams and enhance Stryker's product offerings.
Shows diversification and external validation, which can boost investor confidence.
Manufacturing issue and joint replacement weakness A manufacturing problem limiting inventory and new business is expected to persist into Q4, and joint replacement underperformed on seasonal patterns. These headwinds dragged shares down 7.7% and left SYK down 6.5% YTD.
This is the main negative force that offset strong fundamentals and pressured the stock price.

August 202613 Aug – 8 Sep 2026

▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.
This is the fundamental earnings result that anchors the period's positive momentum.
$100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.
A concrete new contract that adds demand and supports the stock.
Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.
Highlights innovation and strategic growth that drive future revenue and market share.
Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.
This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

Latest13 Aug – 8 Sep 2026

▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.
This is the fundamental earnings result that anchors the period's positive momentum.
$100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.
A concrete new contract that adds demand and supports the stock.
Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.
Highlights innovation and strategic growth that drive future revenue and market share.
Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.
This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

July 202618 Jul – 2 Aug 2026

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.
This is the core fundamental news that answers why SYK is moving and what drives its value.
Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.
This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.
Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.
This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.
Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.
This points to a broader market shift that could lift SYK's stock price through increased demand.

18 Jul – 2 Aug 2026

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.
This is the core fundamental news that answers why SYK is moving and what drives its value.
Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.
This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.
Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.
This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.
Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.
This points to a broader market shift that could lift SYK's stock price through increased demand.

Q2 202622 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

June 202622 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

22 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.